Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2004-02-09
2009-11-10
Carr, Deborah D (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S570000, C554S103000, C554S213000, C554S215000, C554S220000
Reexamination Certificate
active
07615575
ABSTRACT:
Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, artherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; m is 0, 1, 2, 4 or 5; q is 0 or 1; t is 0 or 1; R2is alkyl from 1 to 3 carbon atoms; R3is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by or 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloaldyl having from 3 to 6 ring carbon atoms wherein the cycloaldyl is unsubstitited or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compounds of formula (I) by a ring carbon; and R1is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R1is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).
REFERENCES:
patent: 3976673 (1976-08-01), Pifferi
patent: 4098816 (1978-07-01), Thorne et al.
patent: 4268442 (1981-05-01), Kondo et al.
patent: 4897397 (1990-01-01), Shih et al.
patent: 4939171 (1990-07-01), Moeller et al.
patent: 5589492 (1996-12-01), Haigh
patent: 6677473 (2004-01-01), Madison et al.
patent: 6858602 (2005-02-01), Sharma et al.
patent: 6916848 (2005-07-01), Sharma
patent: 6924314 (2005-08-01), Sharma et al.
patent: 6946491 (2005-09-01), Sharma et al.
patent: 7012071 (2006-03-01), Sharma et al.
patent: 7041659 (2006-05-01), Sharma
patent: 7045541 (2006-05-01), Sharma
patent: 7101910 (2006-09-01), Sharma
patent: 2003/0149107 (2003-08-01), Sharma et al.
patent: 2003/0191323 (2003-10-01), Ikawa et al.
patent: 2004/0092516 (2004-05-01), Sharma et al.
patent: 2004/0214901 (2004-10-01), Antel et al.
patent: 2005/0004115 (2005-01-01), Sharma et al.
patent: 2005/0090555 (2005-04-01), Sharma et al.
patent: 2005/0256333 (2005-11-01), Sharma et al.
patent: 2006/0035970 (2006-02-01), Hodge et al.
patent: 2007/0105955 (2007-05-01), Hodge et al.
patent: 2007/0105958 (2007-05-01), Sharma et al.
patent: 2007/0173544 (2007-07-01), Hodge et al.
patent: 1099701 (2001-05-01), None
patent: 1300142 (2003-04-01), None
patent: 1593667 (2005-11-01), None
patent: 01-216961 (1989-08-01), None
patent: 03-048603 (1991-03-01), None
patent: 08-325250 (1996-12-01), None
patent: 94/05153 (1994-03-01), None
patent: 95/20578 (1995-08-01), None
patent: WO98/03505 (1998-01-01), None
patent: 98/10763 (1998-03-01), None
patent: 9911255 (1999-03-01), None
patent: WO99/11255 (1999-03-01), None
patent: WO99/19291 (1999-04-01), None
patent: 99/54284 (1999-10-01), None
patent: 01/60813 (2001-08-01), None
patent: 02/00341 (2002-12-01), None
patent: WO02/100341 (2002-12-01), None
patent: 2005/019151 (2005-03-01), None
Chemical Abstract DN:128:154084, corresponding to Momose, et al. WO98/03505. See compound RN 152380-68-2.
Chemical Abstract DN: 130: 237567, corresponding to Tajima, et al. WO99/11255. See compounds RN 221258-65-7, 221258-68-0, 221261-93-4, and 221262-95-6.
Chemical Abstract DN: 130:281874, corresponding to Shoda, et al. WO99/19291. See compounds RN 222627-31-8 and 222627-32-9.
Chemical Abstract DN: 65:20620, corresponding to Carlo, BE 667498. See compound RN 6686-26-6.
Faller, “A new solvatochromic chelating agent”, Analytica Chimica Acta, 32(6), 586-9, 1965. Compound having Chemical Abstract RN 186-58-8.
Compound having Chemical Abstract RN 6547-53-1. (known from DE 3017499).
Compound having Chemical Abstract RN 22047-88-7, (known from EP 11279).
Compound having Chemical Abstract RN 64360-35-6, registered before 2001.
Compound having Chemical Abstract RN 76968-92-8, registered before 2001.
Compound having Chemical Abstract RN 136137-46-7, registered before 2001.
Compound having Chemical Abstract RN125721-53-1, registered before 2001.
Compound having Chemical Abstract RN 64360-38-9, registered before 2001.
Compound having Chemical Abstract RN 130604-43-2, registered before 2001.
Compound having Chemical Abstract RN 56441-69-1, registered before 2001.
Compound having Chemical Abstract RN 56441-95-3, registered before 2001.
Compound having Chemical Abstract RN 56441-70-4, registered before 2001.
Compound having Chemical Abstract RN 56441-92-0, registered before 2001.
Compound having Chemical Abstract RN 56441-93-1, registered before 2001.
Compound having Chemical Abstract RN 56441-94-2, registered before 2001.
Compound having Chemical Abstract RN 56441-96-4, registered before 2001.
Compound having Chemical Abstract RN 56442-29-6, registered before 2001.
Compound having Chemical Abstract RN 6388-94-9, registered before 2001.
Jones, “Halogenation of Phenolic Ethers and Anilides. Part XIV m-Substituted Phenyl Esthers”, Journal of the Chemical Society, pp. 430-432, 1943. XP00807474.
Kuchar, et al., “Synthesis of arylacetic acid and their effect on activation of fibrinolysis. Quantitative relations between structure and biological activity”, Collection of Czechoslovak Chemical Communications, 45(5), pp. 1401-1409, 1980. XP-002418932.
Orr, et al., “Improved synthesis of 5-benzyl-2-thiouracils”, Synthetic Communications, 26(1), pp. 179-189, 1996. XP-002418933.
Buu, et al., “Antiinflammatory and analgesic arylacethydroxamic acids”, Chim. Ther., 2(1), pp. 39-48, 1967. XP-002418934.
Kuchar, et al. “The synthesis of arylpropionic acids and the quantitative relationship between the structure and the activation of fibrinolysis”, Collection of Czechoslovak Chemical Communications, 46(5), pp. 1173-1187, 1981. XP-002418936.
Kuchar, et al., “Relationships between gas-liquid chromatographic behavior and structure of aryl-aliphatic acid”, Journal of Chromatograph, 333(1), pp. 21-28, 1985. XP-002418937.
Davies, et al., “Asymmetric Intramolecular C-H Insertions of Aryldiazoacetates”, Organic Letters, 3(10), 1475-1477, 2001. XP-002418938.
Coates, et al., “Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogs of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase”, Journal of Medicinal Chemistry, 36(10), 1387-1392, 1993. XP-002418940.
Maercker, “Cleavage of cyclopropylcarbinyl phenyl ether by alkali metals”, Justus Liebigs Annalen der Chemie, 730, pp. 91-99, 1969. XP-002418941.
Chemical abstract DN 95:150228, also cited as ES488558. XP-002418935.
Chemical abstract DN 139:214465, also cited as WO03070686. XP-002418942.
Chemical abstract DN 141:71356, also cited as W004052839. XP-002418943.
Chemical abstract DN:142:279952, also cited as W005016862. XP-002418944.
Kuchar, et al., “Substituted Benzyloxyarylacetic Acids:Synthesis and Quantitative Relationships Between Structure and Antiinflammatory Activity”, Collection Czech. Chem. Commun., vol. 42(5), pp. 1723-1735, 1977.
Katou, et al., Japanese Patent Application No. 01-216961, published Aug. 30, 1989. (Abstract).
Nakagawa et al., Japanese Patent Application No. 03-048603, published Mar. 1, 1991. (Abstract).
Pending (as of Aug. 20, 2007) claims from U.S. Appl. No. 11/481,508.
Pending (as of Jul. 2, 2007) claims from U.S. Appl. No. 11/772,501.
Pending (as of Jul. 2, 2007) claims from U.S. Appl. No. 11/772,504.
Pending (as of Jul. 2, 2007) claims from U.S. Appl. No. 11/772,511.
Pending (as of Jul. 2, 2007) claims from U.S. Appl. No. 11/772,515.
Pending (as of Jul. 2, 2007) claims from U.S. Appl. No. 11/772,520.
Pending (as of Jul. 2, 2007) claims from U.S. Appl. No. 11/772,556.
Pending (as of Jul. 2, 2007) claims from U.S. Appl. No. 11/772,560.
Pending (as of Aug. 24, 2007) claims from U.S. Appl. No. 11/844,431.
Pending (as of Aug. 24, 2007) claims from U.S. Appl. No. 11/844,432.
Pending (as of Aug. 20, 2007) claims from U.S. Appl. No. 11/841,489.
Pending (as of Sep. 20, 2007) claims
Hodge Kirvin L.
Lee Albert C.
Sharma Shalini
von Borstel Reid W.
Carr Deborah D
Kreisler Lewis J.
Wellstat Therapeutics Corporation
LandOfFree
Compounds for the treatment of metabolic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for the treatment of metabolic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of metabolic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4070780